Conclusions Primary refractory/relapsed DLBCL remains a challenging disease, particularly in those patients who are not eligible for ASCT/CAR-T-cell therapy, failed these treatments or experienced more than one relapse

Conclusions Primary refractory/relapsed DLBCL remains a challenging disease, particularly in those patients who are not eligible for ASCT/CAR-T-cell therapy, failed these treatments or experienced more than one relapse. The landscape of anti-DLBCL treatment is evolving, and only recently, the replacement

This difference in expression may be the result of changes in the expression of the enzymes involved in GalC synthesis, or in the degree to which GalC is capped with sialic acid

This difference in expression may be the result of changes in the expression of the enzymes involved in GalC synthesis, or in the degree to which GalC is capped with sialic acid. cycle. Because epithelial cells collection the female reproductive

Scoumanne for feedback on the final manuscript, the GIGA technology plate-forms (GIGA-Research Centre, Universit de Lige) for help with imaging, circulation cytometry, immunohistochemistry and animal husbandry, and P

Scoumanne for feedback on the final manuscript, the GIGA technology plate-forms (GIGA-Research Centre, Universit de Lige) for help with imaging, circulation cytometry, immunohistochemistry and animal husbandry, and P. Sections of age-matched SCID-Rasa3+/+ (remaining) and moribund SCID-Rasa3?/? (ideal) liver were stained